** Shares of Gland Pharma GLAD.NS fall ~3.3% to 1462.8 rupees
** Co's Q3 revenue falls 10.4% on production setbacks at French unit Cenexi's site near Paris
** Cenexi sales down due to regulatory inspections, breakeven now pushed back by a year vs Q3 target
** Jefferies says Cenexi "continued to bleed" and India and US saw the biggest sales disappointment in Q3
** InCred Equities cuts to 'sell' from 'hold' on "repeated delays in Cenexi's turnaround"
** Citi retains 'sell' on GLAD's inablity to optimize its 'world class' injectables manufacturing set-up
** 10 analysts avg rating is 'hold', avg PT is 1671 rupees, implying ~13.5% upside to current price -LSEG data
** Including session's decline, stock down 27% in last 12 months
(Reporting by Ananta Agarwal in Bengaluru)
((Ananta.Agarwal@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.